| | | | | c-Met targeted therapy of cholangiocarcinoma | | | Matei P Socoteanu;Frank Mott;Gianfranco Alpini;Arthur E Frankel | | | Cholangiocarcinoma continues to be a challenging disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase Ⅱ trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/ hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.
【作者单位】：Scott & White Hospital and Clinics 5701 S;Airport Rd;Temple;Scott & White Hospital and Clinics;5701 S;Airport Rd;Temple;Scott & White Hospital and Clinics;5701 S;Airport Rd;Temple;Scott & White Hospital and Clinics;5701 S;Airport Rd;Temple;Texas 76502;United States;Texas 76502;United States;Texas 76502;United States;Texas 76502;United States
【分类号】：R735.8
【DOI】：CNKI:SUN:ZXXY.0.2008-19-007
【正文快照】：
CHOLANGIOCARCINOMA Cholangiocarcinoma continues to be a challengingdisease to treat. The only curative option remains surgical resection. Recent trends have allowed previously inoperable patients to undergo potentially curative surgery. Most recently, liv… | | |
| | |  推荐 CAJ下载  PDF下载 | | | CAJViewer7.0阅读器支持所有CNKI文件格式，AdobeReader仅支持PDF格式 | | | | c-Met targeted therapy of cholangiocarcinoma | | | Matei P Socoteanu;Frank Mott;Gianfranco Alpini;Arthur E Frankel;Scott & White Hospital and Clinics;5701 S;Airport Rd;Temple;Texas 76502;United States | | | Cholangiocarcinoma continues to be a challenging disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase Ⅱ trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/ hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.
【Keyword】：Cholangiocarcinoma;c-Met;Chemotherapy;Target therapy |
|
|